<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01680757</url>
  </required_header>
  <id_info>
    <org_study_id>RS-001 PLACE III</org_study_id>
    <nct_id>NCT01680757</nct_id>
  </id_info>
  <brief_title>Study of Left Atrial Appendage Closure in Patients With Atrial Fibrillation - III</brief_title>
  <acronym>PLACE III</acronym>
  <official_title>Multicenter Registry of Permanent Ligation Approximation Closure Exclusion of the Left Atrial Appendage in Patients With Atrial Fibrillation III (PLACE III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AtriCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multicenter, non-randomized trial of a stand-alone procedure for&#xD;
      left atrial appendage exclusion in patients with atrial fibrillation at risk for embolic&#xD;
      events who are contraindicated for or intolerant of oral anticoagulation therapy. This study&#xD;
      will enroll 100 participant, who will receive the LAA ligation study treatment. The objective&#xD;
      of this registry is to assess the effectiveness of permanent exclusion of the LAA using the&#xD;
      LARIAT Suture Delivery Device and Accessories in patients unable to be treated with standard&#xD;
      anticoagulation therapy. The results of the study will be used to assess outcomes within the&#xD;
      first year, post-treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study has been withdrawn prior to enrollment&#xD;
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete exclusion</measure>
    <time_frame>During 1 year follow-up.</time_frame>
    <description>To assess the rate of complete exclusion of the left atrial appendage (defined as &lt; 1 mm of communication between left appendage and atrium) measured by color duplex transesophageal echocardiography TEE).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Rate of procedural success</measure>
    <time_frame>Baseline</time_frame>
    <description>Exploratory objectives include assessment of the rate of procedural success (defined as completion of the procedure as intended at baseline, as assessed by the clinical site Principal Investigator)</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of complications</measure>
    <time_frame>During 1 year follow-up</time_frame>
    <description>Exploratory objectives include assessment of the rate of complications related to the use of the LARIAT and accessories</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>LAA exclusion with LARIAT &amp; Accessories</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Permanent exclusion of the LAA using the LARIAT Suture Delivery Device and Accessories</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LARIAT Suture Delivery Device and Accessories</intervention_name>
    <arm_group_label>LAA exclusion with LARIAT &amp; Accessories</arm_group_label>
    <other_name>LARIATTM Suture Delivery Device</other_name>
    <other_name>ENDOCATH Occlusion Balloon</other_name>
    <other_name>SOFTIPTM Guide Cannula</other_name>
    <other_name>FINDRWIRZ Guide Wire System</other_name>
    <other_name>SURECUT Suture Cutter</other_name>
    <other_name>TENSURE Suture Puller</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged â‰¥ 21 years&#xD;
&#xD;
          2. Diagnosed non-valvular atrial fibrillation&#xD;
&#xD;
          3. Current CHADS2 score &gt; 2&#xD;
&#xD;
          4. Currently contraindicated to or intolerant of standard anticoagulation therapy (i.e.,&#xD;
             warfarin, dabigatran, apixaban, and rivaroxaban) due to at least one of the following:&#xD;
             history of bleeding or high risk of bleeding; labile INR level (While on&#xD;
             anticoagulation therapy, participant had INR results &quot;out of therapeutic range&quot; &gt; 40%&#xD;
             of the time, over a minimum period of 2 months.); non-compliant, unwilling to take, or&#xD;
             anticoagulant failure (e.g., TIA or stroke while on anticoagulant therapy).&#xD;
&#xD;
          5. Life expectancy of at least 1 year&#xD;
&#xD;
          6. Willing and able to return and comply with scheduled follow up visits&#xD;
&#xD;
          7. Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior cardiac surgery involving opening of pericardium (e.g., CABG, heart&#xD;
             transplantation, valve surgery)&#xD;
&#xD;
          2. Prosthetic heart valve or ring in any position&#xD;
&#xD;
          3. Current NYHA Class IV heart failure symptoms&#xD;
&#xD;
          4. Current right heart failure&#xD;
&#xD;
          5. Myocardial infarction within last 3 months&#xD;
&#xD;
          6. Unstable angina within last 3 months&#xD;
&#xD;
          7. Current cardiogenic shock or hemodynamic instability&#xD;
&#xD;
          8. Current symptomatic carotid disease&#xD;
&#xD;
          9. Need for an intra-aortic balloon pump or intravenous inotropes&#xD;
&#xD;
         10. Embolic stroke within the last 30 days&#xD;
&#xD;
         11. Transient ischemic attack (TIA) within the last 30 days&#xD;
&#xD;
         12. Current diagnosis of active systemic infection&#xD;
&#xD;
         13. eGFR &lt; 60 mL/min/1.73m2 within last 3 months&#xD;
&#xD;
         14. Current renal failure requiring dialysis&#xD;
&#xD;
         15. ALT or AST level &gt; 3 times upper level of normal, indicating hepatic failure. (NOTE:&#xD;
             normal range provided by local laboratory performing the measurement), based on most&#xD;
             recent pre-procedure assessment (within 30 days of study treatment)&#xD;
&#xD;
         16. Current clinical evidence of cirrhosis&#xD;
&#xD;
         17. Any history of thoracic radiation&#xD;
&#xD;
         18. Current use of long term treatment with steroids, not including intermittent use of&#xD;
             inhaled steroids for respiratory diseases&#xD;
&#xD;
         19. Diagnosed autoimmune disease known to be associated with pericarditis (i.e., specific&#xD;
             connective tissue disorders)&#xD;
&#xD;
         20. Any history of pericarditis&#xD;
&#xD;
         21. Pectus excavatum (clinically defined by treating physician)&#xD;
&#xD;
         22. Severe scoliosis&#xD;
&#xD;
         23. Thrombocytopenia (platelet count &lt; 100 x 109/L) based on most recent pre-procedure&#xD;
             assessment (within 30 days of study treatment)&#xD;
&#xD;
         24. Anemia with hemoglobin concentration of &lt; 10 g/dL based on most recent pre-procedure&#xD;
             assessment (within 30 days of study treatment)&#xD;
&#xD;
         25. Pregnancy or desire to get pregnant within next 12 months.&#xD;
&#xD;
         26. Current enrollment in an investigation or study of a cardiovascular device or&#xD;
             investigational drug that would interfere with this registry&#xD;
&#xD;
         27. Mental impairment or other conditions, which may not allow patient to understand the&#xD;
             nature, significance and scope of the study&#xD;
&#xD;
         28. Any other criteria, which would make the patient unsuitable to participate in this&#xD;
             study as determined by clinical site Principal Investigator (e.g., an uncontrolled&#xD;
             drug and/or alcohol addiction)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Marcus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Good Samaritan</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Green Hospital and Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital and Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60327</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Paul II Hospital</name>
      <address>
        <city>Krakow</city>
        <zip>31202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>August 28, 2012</study_first_submitted>
  <study_first_submitted_qc>September 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2012</study_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left Atrial Appendage</keyword>
  <keyword>LARIAT</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>contraindication to oral anticoagulation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

